



# News Release

## FOR IMMEDIATE RELEASE

### **OvaScience Chief Executive Officer Selected Entrepreneur of The Year 2013 Finalist for New England by Ernst & Young**

**CAMBRIDGE, Mass., June 3, 2013** – [OvaScience<sup>SM</sup>](#), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp, M.D., Ph.D., fertility advocate, co-founder and Chief Executive Officer, has been selected as a finalist for the Ernst & Young Entrepreneur Of The Year<sup>®</sup> 2013 Awards in New England. Finalists were chosen by a panel of judges who have recognized the company's outstanding accomplishments in such areas as innovation, financial performance and personal commitment to their businesses and communities. Award winners will be announced at a special gala event on Wednesday, June 26, 2013 in Boston.

“The Ernst & Young Entrepreneur of the Year Award for New England acknowledges the most innovative companies and individuals in the region,” said Rich Aldrich, Co-Founder and Chairman of the Board of Directors of OvaScience. “Since its founding, OvaScience has made great progress in translating the groundbreaking scientific discovery of egg precursor cells into potential new treatments for female infertility. We are pleased that Michelle and OvaScience have gained this recognition at such an important time in the Company's evolution.”

Ernst & Young is a global leader in assurance, tax, transaction and advisory services and their Entrepreneur Of The Year is the world's most prestigious business award for entrepreneurs. The unique award recognizes the significant contributions of entrepreneurs who inspire others with their vision, leadership and achievement. Now in its 27th year, the Entrepreneur Of The Year Program has expanded globally to recognize company builders in over 140 cities and in more than 50 countries throughout the world. Regional award winners go on to compete at the national level.

#### **About OvaScience**

OvaScience (NASDAQ: OVAS) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company's patented technology is based on the discovery of egg precursor cells (EggPC<sup>SM</sup>), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENT<sup>SM</sup> aims to improve egg quality and increase the success of *in vitro* fertilization (IVF). OvaScience's team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit [www.ovascience.com](http://www.ovascience.com) and connect with us on [Twitter](#) and [Facebook](#).

#### **Forward-Looking Statements**

*This press release includes forward-looking statements about the Company's strategy, future plans and prospects, including statements regarding the development and planned launch of the Company's product candidates, including AUGMENT. Any statements in this release about our strategy, plans, prospects and future expectations, financial*

*position and operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “aim,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates, which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.*

**Contact:**

Theresa McNeely  
EVP, Strategic Corporate Communications  
OvaScience, Inc.  
[tmcneely@ovascience.com](mailto:tmcneely@ovascience.com)  
617-299-7356

###